OGN Stock Overview
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 0/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.61 |
| 52 Week High | US$24.08 |
| 52 Week Low | US$10.84 |
| Beta | 0.79 |
| 1 Month Change | 9.49% |
| 3 Month Change | 17.85% |
| 1 Year Change | -12.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.02% |
Recent News & Updates
Recent updates
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21
Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN)
Nov 05Organon: Thoughts Ahead Of Q3 Earnings
Oct 31Organon: What Is The Recipe?
Aug 31Oragenics announces early toxicology data for intranasal COVID-19 vaccine
Aug 24Organon, Samsung Bioepis Humira biosimilar Hadlima high concentration dosage gets FDA nod
Aug 17Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Aug 07Organon Q2 2022 Earnings Preview
Aug 03Organon in pact with Cirqle Biomedical for contraceptive candidate
Jul 28Organon: Some Uncomfortable Questions Ahead Of Q2 Earnings
Jul 18Organon Vs. Viatris: Who Is The Clear Winner?
Jun 20Organon: Maximum Optimism
Apr 28Viatris Vs. Organon: Surprisingly Undervalued, But Which Is The Better Buy?
Feb 19Shareholder Returns
| OGN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.7% | 1.1% | 0.7% |
| 1Y | -12.9% | 9.5% | 23.9% |
Return vs Industry: OGN underperformed the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: OGN underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| OGN volatility | |
|---|---|
| OGN Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OGN has not had significant price volatility in the past 3 months.
Volatility Over Time: OGN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| OGN fundamental statistics | |
|---|---|
| Market cap | US$5.01b |
| Earnings (TTM) | US$1.05b |
| Revenue (TTM) | US$6.35b |
4.8x
P/E Ratio0.8x
P/S RatioIs OGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OGN income statement (TTM) | |
|---|---|
| Revenue | US$6.35b |
| Cost of Revenue | US$2.61b |
| Gross Profit | US$3.74b |
| Other Expenses | US$2.69b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.07 |
| Gross Margin | 58.93% |
| Net Profit Margin | 16.50% |
| Debt/Equity Ratio | -12,758.6% |
How did OGN perform over the long term?
See historical performance and comparison